2019
Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study
Harris HR, Cushing-Haugen KL, Webb PM, Nagle CM, Jordan SJ, Group A, Risch H, Rossing M, Doherty J, Goodman M, Modugno F, Ness R, Moysich K, Kjær S, Høgdall E, Jensen A, Schildkraut J, Berchuck A, Cramer D, Bandera E, Rodriguez L, Wentzensen N, Kotsopoulos J, Narod S, McLaughlin J, Anton-Culver H, Ziogas A, Pearce C, Wu A, Lindström S, Terry K. Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. International Journal Of Epidemiology 2019, 48: 822-830. PMID: 31211375, PMCID: PMC6659359, DOI: 10.1093/ije/dyz113.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeOvarian cancer riskOvarian Cancer Association ConsortiumSelf-reported polycystic ovary syndromeInvasive ovarian cancerOvarian cancerCancer riskOvary syndromeInverse associationOral contraceptive useReproductive-aged womenBody mass indexSingle nucleotide polymorphismsStrong inverse associationComplex endocrine disorderObservational study resultsMendelian randomization studyEuropean ancestry womenEndometrioid tumorsMass indexDecreased riskEndocrine disordersSpecific histotypesContraceptive useAged women
2016
Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer
Fu Y, Biglia N, Wang Z, Shen Y, Risch HA, Lu L, Canuto EM, Jia W, Katsaros D, Yu H. Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer. Gynecologic Oncology 2016, 143: 642-649. PMID: 27667152, PMCID: PMC5507336, DOI: 10.1016/j.ygyno.2016.09.021.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdenocarcinoma, Clear CellAdultAgedAged, 80 and overCarcinoma, EndometrioidCarcinoma, Ovarian EpithelialHumansMiddle AgedNeoplasm GradingNeoplasm StagingNeoplasms, Cystic, Mucinous, and SerousNeoplasms, Glandular and EpithelialOvarian NeoplasmsPrognosisProportional Hazards ModelsReverse Transcriptase Polymerase Chain ReactionRNA, Long NoncodingYoung AdultConceptsEpithelial ovarian cancerOvarian cancerStage diseasePatient survivalGrade tumorsASAP1-IT1Survival associationsLong non-coding RNAsCox proportional hazards regression modelPrimary epithelial ovarian cancerProportional hazards regression modelsTumor samplesFresh frozen tumor samplesHigh expressionEarly-stage diseaseFavorable overall survivalLate-stage diseaseHazards regression modelsLow-grade tumorsHigh-grade tumorsOvarian cancer progressionNon-coding RNAsImportant biological actionsOverall survivalPoor prognosisAssociation Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk
Lee AW, Ness RB, Roman LD, Terry KL, Schildkraut JM, Chang-Claude J, Doherty JA, Menon U, Cramer DW, Gayther SA, Risch H, Gentry-Maharaj A, Goodman MT, Modugno F, Eilber U, Moysich KB, Berchuck A, Rossing MA, Jensen A, Wicklund KG, Cushing-Haugen KL, Hogdall E, Rudolph A, Thompson PJ, Wilkens LR, Kjaer SK, Carney ME, Stram DO, Ramus SJ, Wu AH, Pike MC, Pearce CL. Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. Obstetrics And Gynecology 2016, 127: 828-836. PMID: 27054934, PMCID: PMC4892111, DOI: 10.1097/aog.0000000000001387.Peer-Reviewed Original ResearchConceptsEndometrioid ovarian carcinomaTherapy useOvarian carcinomaPostmenopausal estrogenControl groupPopulation-based case-control studyCase-control studyOvarian carcinoma histotypesOvarian carcinoma riskConditional logistic regressionOvarian Cancer Association ConsortiumSerous ovarian carcinomaDuration of useTiming of useTherapy usersMenopausal estrogensPooled analysisRisk factorsSelf-reported questionnaire dataCarcinoma riskCarcinomaEstrogenRecent usersLogistic regressionHistotype
2015
Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
Salmena L, Shaw P, Fans I, McLaughlin, Rosen B, Risch H, Mitchell C, Sun P, Narod SA, Kotsopoulos J. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer. European Journal Of Gynaecological Oncology 2015, 36: 260-7. PMID: 26189250.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdultAgedBiomarkers, TumorCarcinoma, EndometrioidCarcinoma, Ovarian EpithelialFemaleHumansImmunohistochemistryMiddle AgedNeoplasm StagingNeoplasms, Cystic, Mucinous, and SerousNeoplasms, Glandular and EpithelialOvarian NeoplasmsPhosphoric Monoester HydrolasesPrognosisProportional Hazards ModelsPTEN PhosphohydrolaseTumor Suppressor Protein p53Young AdultConceptsAberrant p53 expressionOvarian cancerP53 expressionHazard ratioLoss of PTENOvarian tumorsOvarian cancer tissue samplesEndometrioid ovarian tumorsProtein expressionSurvival hazard ratioEpithelial ovarian tumorsPoor disease outcomePossible prognostic roleProportional hazards modelCancer tissue samplesPrognostic roleEndometrioid tumorsEndometrioid subtypePrognostic valuePoor prognosisSerous subtypeProtein immunohistochemistryDisease outcomeTissue microarrayHazards model
2013
Type I and II Endometrial Cancers: Have They Different Risk Factors?
Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, Wolk A, Wentzensen N, Weiss NS, Webb PM, van den Brandt PA, van de Vijver K, Thompson PJ, Group T, Strom BL, Spurdle AB, Soslow RA, Shu XO, Schairer C, Sacerdote C, Rohan TE, Robien K, Risch HA, Ricceri F, Rebbeck TR, Rastogi R, Prescott J, Polidoro S, Park Y, Olson SH, Moysich KB, Miller AB, McCullough ML, Matsuno RK, Magliocco AM, Lurie G, Lu L, Lissowska J, Liang X, Lacey JV, Kolonel LN, Henderson BE, Hankinson SE, Håkansson N, Goodman MT, Gaudet MM, Garcia-Closas M, Friedenreich CM, Freudenheim JL, Doherty J, De Vivo I, Courneya KS, Cook LS, Chen C, Cerhan JR, Cai H, Brinton LA, Bernstein L, Anderson KE, Anton-Culver H, Schouten LJ, Horn-Ross PL. Type I and II Endometrial Cancers: Have They Different Risk Factors? Journal Of Clinical Oncology 2013, 31: 2607-2618. PMID: 23733771, PMCID: PMC3699726, DOI: 10.1200/jco.2012.48.2596.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAge FactorsAgedBiopsy, NeedleCarcinoma, EndometrioidCase-Control StudiesCohort StudiesConfidence IntervalsContraceptives, OralDatabases, FactualDiabetes MellitusDisease-Free SurvivalEndometrial NeoplasmsFemaleHumansImmunohistochemistryMiddle AgedNeoplasm InvasivenessNeoplasm StagingObesityOdds RatioRisk FactorsSensitivity and SpecificitySmokingSurvival AnalysisConceptsType II tumorsII tumorsRisk factorsEndometrial cancerOdds ratioHigh-grade endometrioid tumorsEndometrial cancer risk factorsType IEndometrial Cancer ConsortiumEndometrial cancer typesType I tumorsEndometrial cancer casesOral contraceptive useRisk factor patternsBody mass indexCancer risk factorsCommon etiologic factorCase-control studyDifferent risk factorsEndometrioid tumorsI tumorsMass indexCigarette smokingPooled analysisEtiologic factors
2010
Physical activity and endometrial cancer in a population-based case–control study
Arem H, Irwin ML, Zhou Y, Lu L, Risch H, Yu H. Physical activity and endometrial cancer in a population-based case–control study. Cancer Causes & Control 2010, 22: 219-226. PMID: 21110224, PMCID: PMC3075067, DOI: 10.1007/s10552-010-9689-0.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskLower endometrial cancer riskMET h/wkPhysical activityCancer riskEndometrial cancerRisk factorsPopulation-based case-control studyInterview-administered questionnaireMetabolic equivalent hoursPhysical Activity QuestionnaireUnconditional logistic regressionRecreational physical activityCase-control studyAge-matched controlsPhysical activity dataIncident casesActivity QuestionnaireIndependent associationConclusionOur dataLifestyle informationBMILogistic regressionReference groupCancer
2008
Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the ovarian cancer association consortium pooled analysis
Pearce CL, Wu AH, Gayther SA, Bale AE, Beck P, Beesley J, Chanock S, Cramer D, DiCioccio R, Edwards R, Fredericksen Z, Garcia-Closas M, Goode E, Green A, Hartmann L, Hogdall E, Kjær S, Lissowska J, McGuire V, Modugno F, Moysich K, Ness R, Ramus S, Risch H, Sellers T, Song H, Stram D, Terry K, Webb P, Whiteman D, Whittemore A, Zheng W, Pharoah P, Chenevix-Trench G, Pike M, Schildkraut J, Berchuck A, on behalf of the Ovarian Cancer Association Consortium (OCAC). Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the ovarian cancer association consortium pooled analysis. British Journal Of Cancer 2008, 98: 282-288. PMID: 18219286, PMCID: PMC2361465, DOI: 10.1038/sj.bjc.6604170.Peer-Reviewed Original ResearchConceptsEndometrioid ovarian cancerOvarian cancer riskProgesterone receptor geneCase-control studyOvarian cancerCancer riskSingle nucleotide polymorphismsPGR single-nucleotide polymorphismInvasive epithelial ovarian cancerOvarian cancer case-control studiesEpithelial ovarian cancerUnconditional logistic regressionCancer case-control studyOvarian cancer casesOvarian Cancer Association ConsortiumTwo-sided p valueEndometrioid subtypePROGINS alleleCancer casesBorderline evidencePROGINS variantSubtype analysisSignificant associationT variantCancer
1996
Estrogen Replacement Therapy and Risk of Epithelial Ovarian Cancer
Risch H. Estrogen Replacement Therapy and Risk of Epithelial Ovarian Cancer. Gynecologic Oncology 1996, 63: 254-257. PMID: 8910636, DOI: 10.1006/gyno.1996.0315.Peer-Reviewed Original ResearchConceptsEstrogen replacement therapyEpithelial ovarian cancerOvarian cancerReplacement therapyRelative oddsInvasive epithelial ovarian cancerMultivariate logistic regression analysisHistology-specific analysisNonmucinous ovarian cancerOral contraceptive usageLogistic regression analysisERT usageERT useMucinous tumorsTumor histologyMenopausal womenSerous carcinomaEndometrioid carcinomaHistologic groupsNonmucinous typeCancerCarcinomaRegression analysisPopulation controlsTherapy